Compare LIN & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIN | GRI |
|---|---|---|
| Founded | 1879 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.0B | 4.3M |
| IPO Year | N/A | N/A |
| Metric | LIN | GRI |
|---|---|---|
| Price | $416.10 | $0.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $500.36 | $23.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 10-31-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 13.37 | N/A |
| EPS | ★ 14.94 | N/A |
| Revenue | ★ $33,504,000,000.00 | N/A |
| Revenue This Year | $3.72 | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | $27.86 | ★ N/A |
| Revenue Growth | ★ 1.45 | N/A |
| 52 Week Low | $387.78 | $0.50 |
| 52 Week High | $486.38 | $16.66 |
| Indicator | LIN | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 22.14 |
| Support Level | $389.00 | $0.50 |
| Resistance Level | $411.58 | $2.17 |
| Average True Range (ATR) | 6.85 | 0.19 |
| MACD | 1.57 | -0.16 |
| Stochastic Oscillator | 94.18 | 0.85 |
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2024.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.